Medicare Just Announced Its 2026 Premiums, and It's Bad News for Social Security's Dual Enrollees

The Social Security Administration set the 2026 COLA at 2.8% based on September inflation—marking the fifth consecutive year with a COLA of 2.5% or higher, the longest streak since 1988–1997—while CMS announced a Medicare Part B premium of $202.90/month for 2026, a 9.7% year-over-year increase (slightly below the trustees’ $206.20 estimate) driven by higher costs for physician-administered drugs and outpatient care. Because Part B premiums are typically deducted from Social Security checks, the near-double-digit premium rise is likely to partially or fully offset the modest COLA for dual enrollees—especially low earners—highlighting a persistent disconnect between Social Security benefit adjustments and healthcare cost inflation that erodes retirees’ real purchasing power.

Analysis

The Social Security Administration set the 2026 COLA at 2.8% based on September inflation data, marking the fifth consecutive year with a COLA at or above 2.5% — the longest such streak since 1988–1997. Nominally 2.8% is modest relative to the outsized increases from 2022–2024 (5.9%, 8.7%, 3.2%), but it is above the 2010–present average of 2.3% and continues an above-average run.

The Centers for Medicare & Medicaid Services finalized the 2026 Medicare Part B premium at $202.90/month, a 9.7% year-over-year increase and slightly below the Trustees’ mid‑June estimate of $206.20 (an 11.5% projection). CMS cites higher costs for physician-administered drugs and outpatient care as drivers, and because Part B is generally deducted from Social Security checks for dual enrollees, the premium rise can materially erode the real benefit increase for retirees — especially lifetime low earners.

The divergence between healthcare cost growth and Social Security COLAs highlights a sustained purchasing‑power risk for retirees; historical outlays (including a rare Part B decline in 2023) have proven volatile and can negate COLA gains. Stakeholders should treat Medicare premium announcements and drug-cost trends as primary leads when stress‑testing retiree cash flows and income-sensitive sector exposure.

Key Decisions for Investors

• Model the net income impact for dual enrollees by offsetting the 2.8% COLA against a 9.7% Part B premium increase and stress-test portfolios for low‑earner cohorts
• Increase near-term liquidity or cashflow cushions for client accounts concentrated in retirement income to cover likely higher out‑of‑pocket healthcare costs
• Monitor CMS updates and physician‑administered drug cost trends as key catalysts for further premium changes and adjust assumptions for retiree spending and credit risk accordingly
• Consider modest tilt toward instruments and strategies that preserve purchasing power for retirees (short-duration income, inflation protection or higher-yielding conservative income) while avoiding overexposure to discretionary consumer sectors reliant on retiree spending